Which of the following agents is available as a patch for once-daily use and is likely to provide steady drug levels to treat Alzheimer's disease?

Correct Answer: A

Rationale: Rivastigmine, an acetylcholinesterase inhibitor, treats Alzheimer's by increasing acetylcholine, improving cognition. Its transdermal patch delivers steady drug levels daily, minimizing peaks/troughs and reducing GI side effects (e.g., nausea) compared to oral forms, enhancing compliance. Donepezil, memantine, and galantamine are oral, lacking a once-daily patch; donepezil's long half-life mimics steady-state but isn't transdermal. Glatiramer treats MS, not Alzheimer's. Rivastigmine's patch formulation ensures consistent cholinergic enhancement, critical for sustained symptom relief in Alzheimer's, distinguishing it as the optimal choice here.

Correct Answer: B

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Correct Answer: C

Rationale: Amitriptyline, a tricyclic antidepressant, has anticholinergic effects, including urinary retention , a medical emergency risking bladder damage or infection, needing immediate intervention. Dry mouth and constipation are common, manageable side effects. Drowsiness is expected with its sedative action. Urinary retention's severity'potential for acute retention'sets it apart, requiring rapid reporting or catheterization. This aligns with amitriptyline's blockade of muscarinic receptors, where bladder dysfunction can escalate fast, making C the finding demanding urgent attention over chronic annoyances.

Correct Answer: D

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.